VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q58234406 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241121000223.0
008 241121nneanz||abbn n and d
035 ‎‡a (WKP)Q58234406‏
024 ‎‡a 0000-0001-9529-6550‏ ‎‡2 orcid‏
035 ‎‡a (OCoLC)Q58234406‏
100 0 ‎‡a Tao Liu‏ ‎‡c researcher, ORCID id # 0000-0001-9529-6550‏ ‎‡9 en‏
670 ‎‡a Author's A systematic analysis of a deep mouse epididymal sperm proteome‏
670 ‎‡a Author's Accurate mass measurements in proteomics.‏
670 ‎‡a Author's Advances and challenges in liquid chromatography-mass spectrometry-based proteomics profiling for clinical applications‏
670 ‎‡a Author's Advancing the sensitivity of selected reaction monitoring-based targeted quantitative proteomics‏
670 ‎‡a Author's An improved Boosting to Amplify Signal with Isobaric Labeling (iBASIL) strategy for precise quantitative single-cell proteomics‏
670 ‎‡a Author's An Integrative Analysis of Tumor Proteomic and Phosphoproteomic Profiles to Examine the Relationships Between Kinase Activity and Phosphorylation‏
670 ‎‡a Author's Analysis of recombinant and modified proteins by capillary zone electrophoresis coupled with electrospray ionization tandem mass spectrometry‏
670 ‎‡a Author's Analysis of serum total and free PSA using immunoaffinity depletion coupled to SRM: correlation with clinical immunoassay tests‏
670 ‎‡a Author's Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum‏
670 ‎‡a Author's Application of free-flow electrophoresis to the purification of trichosanthin from a crude product of acetone fractional precipitation.‏
670 ‎‡a Author's Automated Nanoflow Two-Dimensional Reversed-Phase Liquid Chromatography System Enables In-Depth Proteome and Phosphoproteome Profiling of Nanoscale Samples‏
670 ‎‡a Author's Blood peptidome-degradome profile of breast cancer‏
670 ‎‡a Author's Boosting to Amplify Signal with Isobaric Labeling‏
670 ‎‡a Author's Boosting to Amplify Signal with Isobaric Labeling (BASIL) Strategy for Comprehensive Quantitative Phosphoproteomic Characterization of Small Populations of Cells.‏
670 ‎‡a Author's Carrier-Assisted Single-Tube Processing Approach for Targeted Proteomics Analysis of Low Numbers of Mammalian Cells‏
670 ‎‡a Author's Characterization of the mouse brain proteome using global proteomic analysis complemented with cysteinyl-peptide enrichment‏
670 ‎‡a Author's Deep-Dive Targeted Quantification for Ultrasensitive Analysis of Proteins in Nondepleted Human Blood Plasma/Serum and Tissues.‏
670 ‎‡a Author's Detection of head and neck cancer based on longitudinal changes in serum protein abundance‏
670 ‎‡a Author's Distinct cerebrospinal fluid proteomes differentiate post-treatment lyme disease from chronic fatigue syndrome‏
670 ‎‡a Author's Enhanced detection of low abundance human plasma proteins using a tandem IgY12-SuperMix immunoaffinity separation strategy.‏
670 ‎‡a Author's Enhanced sensitivity for selected reaction monitoring mass spectrometry-based targeted proteomics using a dual stage electrodynamic ion funnel interface.‏
670 ‎‡a Author's Establishing the proteome of normal human cerebrospinal fluid‏
670 ‎‡a Author's Evaluation of Differential Peptide Loading on Tandem Mass Tag-Based Proteomic and Phosphoproteomic Data Quality‏
670 ‎‡a Author's Evaluation of multiprotein immunoaffinity subtraction for plasma proteomics and candidate biomarker discovery using mass spectrometry.‏
670 ‎‡a Author's Facile carrier-assisted targeted mass spectrometric approach for proteomic analysis of low numbers of mammalian cells‏
670 ‎‡a Author's Facile One-Pot Nanoproteomics for Label-Free Proteome Profiling of 50-1000 Mammalian Cells‏
670 ‎‡a Author's Head-to-Head Comparison of Serum Fractionation Techniques‏
670 ‎‡a Author's High dynamic range characterization of the trauma patient plasma proteome‏
670 ‎‡a Author's High-throughput and high-efficiency sample preparation for single-cell proteomics using a nested nanowell chip‏
670 ‎‡a Author's High-throughput comparative proteome analysis using a quantitative cysteinyl-peptide enrichment technology.‏
670 ‎‡a Author's High-Throughput Single Cell Proteomics Enabled by Multiplex Isobaric Labeling in a Nanodroplet Sample Preparation Platform‏
670 ‎‡a Author's Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry‏
670 ‎‡a Author's Improved proteome coverage by using high efficiency cysteinyl peptide enrichment: the human mammary epithelial cell proteome‏
670 ‎‡a Author's Improved Sensitivity and Separations for Phosphopeptides using Online Liquid Chromotography Coupled with Structures for Lossless Ion Manipulations Ion Mobility-Mass Spectrometry‏
670 ‎‡a Author's Investigating the correspondence between transcriptomic and proteomic expression profiles using coupled cluster models‏
670 ‎‡a Author's Large-scale multiplexed quantitative discovery proteomics enabled by the use of an‏
670 ‎‡a Author's Large-scale multiplexed quantitative discovery proteomics enabled by the use of an (18)O-labeled "universal" reference sample‏
670 ‎‡a Author's Liquid chromatography-mass spectrometry-based quantitative proteomics.‏
670 ‎‡a Author's Mapping N-linked glycosylation sites in the secretome and whole cells of Aspergillus niger using hydrazide chemistry and mass spectrometry.‏
670 ‎‡a Author's Mass spectrometry for translational proteomics: progress and clinical implications‏
670 ‎‡a Author's Network analysis of epidermal growth factor signaling using integrated genomic, proteomic and phosphorylation data‏
670 ‎‡a Author's Pan-cancer proteogenomic investigations identify post-transcriptional kinase targets‏
670 ‎‡a Author's Phosphoproteome Analysis Reveals Estrogen-ER Pathway as a Modulator of mTOR Activity Via DEPTOR‏
670 ‎‡a Author's Probability-based evaluation of peptide and protein identifications from tandem mass spectrometry and SEQUEST analysis: the human proteome‏
670 ‎‡a Author's Proteome and transcriptome profiles of a Her2/Neu-driven mouse model of breast cancer‏
670 ‎‡a Author's Proteomic Analysis of Exosomes for Discovery of Protein Biomarkers for Prostate and Bladder Cancer‏
670 ‎‡a Author's Proteomic Tissue-Based Classifier for Early Prediction of Prostate Cancer Progression‏
670 ‎‡a Author's Quality Assessments of Long-Term Quantitative Proteomic Analysis of Breast Cancer Xenograft Tissues.‏
670 ‎‡a Author's Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics‏
670 ‎‡a Author's Quantitative analysis of human immunodeficiency virus type 1-infected CD4+ cell proteome: dysregulated cell cycle progression and nuclear transport coincide with robust virus production‏
670 ‎‡a Author's Quantitative proteome analysis of human plasma following in vivo lipopolysaccharide administration using 16O/18O labeling and the accurate mass and time tag approach.‏
670 ‎‡a Author's Quantitative proteomics analysis of adsorbed plasma proteins classifies nanoparticles with different surface properties and size‏
670 ‎‡a Author's Quantitative proteomics identifies altered O-GlcNAcylation of structural, synaptic and memory-associated proteins in Alzheimer's disease‏
670 ‎‡a Author's Rapidly Assessing the Quality of Targeted Proteomics Experiments through Monitoring Stable-Isotope Labeled Standards.‏
670 ‎‡a Author's Regulated Phosphosignaling Associated with Breast Cancer Subtypes and Druggability‏
670 ‎‡a Author's Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography-mass spectrometry‏
670 ‎‡a Author's Reversed-phase chromatography with multiple fraction concatenation strategy for proteome profiling of human MCF10A cells‏
670 ‎‡a Author's Simple sodium dodecyl sulfate-assisted sample preparation method for LC-MS-based proteomics applications‏
670 ‎‡a Author's Spatial mapping of the neurite and soma proteomes reveals a functional Cdc42/Rac regulatory network‏
670 ‎‡a Author's Strategy for degradomic-peptidomic analysis of human blood plasma‏
670 ‎‡a Author's Surfactant-assisted one-pot sample preparation for label-free single-cell proteomics‏
670 ‎‡a Author's Tandem Mass Tag Labeling Facilitates Reversed-Phase Liquid Chromatography-Mass Spectrometry Analysis of Hydrophilic Phosphopeptides‏
670 ‎‡a Author's Targeted Quantification of Phosphorylation Dynamics in the Context of EGFR-MAPK Pathway.‏
670 ‎‡a Author's The use of a quantitative cysteinyl-peptide enrichment technology for high-throughput quantitative proteomics.‏
670 ‎‡a Author's Utilizing human blood plasma for proteomic biomarker discovery‏
909 ‎‡a (orcid) 0000000195296550‏ ‎‡9 1‏
919 ‎‡a highthroughputsinglecellproteomicsenabledbymultiplexisobariclabelinginananodropletsamplepreparationplatform‏ ‎‡A High-Throughput Single Cell Proteomics Enabled by Multiplex Isobaric Labeling in a Nanodroplet Sample Preparation Platform‏ ‎‡9 1‏
919 ‎‡a humanplasmanglycoproteomeanalysisbyimmunoaffinitysubtractionhydrazidechemistryandmassspectrometry‏ ‎‡A Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry‏ ‎‡9 1‏
919 ‎‡a improvedproteomecoveragebyusinghighefficiencycysteinylpeptideenrichmentthehumanmammaryepithelialcellproteome‏ ‎‡A Improved proteome coverage by using high efficiency cysteinyl peptide enrichment: the human mammary epithelial cell proteome‏ ‎‡9 1‏
919 ‎‡a improvedsensitivityandseparationsforphosphopeptidesusingonlineliquidchromotographycoupledwithstructuresforlosslessionmanipulationsionmobilitymassspectrometry‏ ‎‡A Improved Sensitivity and Separations for Phosphopeptides using Online Liquid Chromotography Coupled with Structures for Lossless Ion Manipulations Ion Mobility-Mass Spectrometry‏ ‎‡9 1‏
919 ‎‡a investigatingthecorrespondencebetweentranscriptomicandproteomicexpressionprofilesusingcoupledclustermodels‏ ‎‡A Investigating the correspondence between transcriptomic and proteomic expression profiles using coupled cluster models‏ ‎‡9 1‏
919 ‎‡a largescalemultiplexedquantitativediscoveryproteomicsenabledbytheuseofan‏ ‎‡A Large-scale multiplexed quantitative discovery proteomics enabled by the use of an‏ ‎‡9 1‏
919 ‎‡a largescalemultiplexedquantitativediscoveryproteomicsenabledbytheuseofan18olabeleduniversalreferencesample‏ ‎‡A Large-scale multiplexed quantitative discovery proteomics enabled by the use of an (18)O-labeled "universal" reference sample‏ ‎‡9 1‏
919 ‎‡a liquidchromatographymassspectrometrybasedquantitativeproteomics‏ ‎‡A Liquid chromatography-mass spectrometry-based quantitative proteomics.‏ ‎‡9 1‏
919 ‎‡a mappingnlinkedglycosylationsitesinthesecretomeandwholecellsofaspergillusnigerusinghydrazidechemistryandmassspectrometry‏ ‎‡A Mapping N-linked glycosylation sites in the secretome and whole cells of Aspergillus niger using hydrazide chemistry and mass spectrometry.‏ ‎‡9 1‏
919 ‎‡a massspectrometryfortranslationalproteomicsprogressandclinicalimplications‏ ‎‡A Mass spectrometry for translational proteomics: progress and clinical implications‏ ‎‡9 1‏
919 ‎‡a networkanalysisofepidermalgrowthfactorsignalingusingintegratedgenomicproteomicandphosphorylationdata‏ ‎‡A Network analysis of epidermal growth factor signaling using integrated genomic, proteomic and phosphorylation data‏ ‎‡9 1‏
919 ‎‡a pancancerproteogenomicinvestigationsidentifyposttranscriptionalkinasetargets‏ ‎‡A Pan-cancer proteogenomic investigations identify post-transcriptional kinase targets‏ ‎‡9 1‏
919 ‎‡a phosphoproteomeanalysisrevealsestrogenerpathwayasamodulatorofmtoractivityviadeptor‏ ‎‡A Phosphoproteome Analysis Reveals Estrogen-ER Pathway as a Modulator of mTOR Activity Via DEPTOR‏ ‎‡9 1‏
919 ‎‡a probabilitybasedevaluationofpeptideandproteinidentificationsfromtandemmassspectrometryandsequestanalysisthehumanproteome‏ ‎‡A Probability-based evaluation of peptide and protein identifications from tandem mass spectrometry and SEQUEST analysis: the human proteome‏ ‎‡9 1‏
919 ‎‡a proteomeandtranscriptomeprofilesofaher2neudrivenmousemodelofbreastcancer‏ ‎‡A Proteome and transcriptome profiles of a Her2/Neu-driven mouse model of breast cancer‏ ‎‡9 1‏
919 ‎‡a proteomicanalysisofexosomesfordiscoveryofproteinbiomarkersforprostateandbladdercancer‏ ‎‡A Proteomic Analysis of Exosomes for Discovery of Protein Biomarkers for Prostate and Bladder Cancer‏ ‎‡9 1‏
919 ‎‡a proteomictissuebasedclassifierforearlypredictionofprostatecancerprogression‏ ‎‡A Proteomic Tissue-Based Classifier for Early Prediction of Prostate Cancer Progression‏ ‎‡9 1‏
919 ‎‡a qualityassessmentsoflongtermquantitativeproteomicanalysisofbreastcancerxenografttissues‏ ‎‡A Quality Assessments of Long-Term Quantitative Proteomic Analysis of Breast Cancer Xenograft Tissues.‏ ‎‡9 1‏
919 ‎‡a quantificationofmutantspopproteinsinprostatecancerusingmassspectrometrybasedtargetedproteomics‏ ‎‡A Quantification of mutant SPOP proteins in prostate cancer using mass spectrometry-based targeted proteomics‏ ‎‡9 1‏
919 ‎‡a quantitativeanalysisofhumanimmunodeficiencyvirustype1infectedcd4+cellproteomedysregulatedcellcycleprogressionandnucleartransportcoincidewithrobustvirusproduction‏ ‎‡A Quantitative analysis of human immunodeficiency virus type 1-infected CD4+ cell proteome: dysregulated cell cycle progression and nuclear transport coincide with robust virus production‏ ‎‡9 1‏
919 ‎‡a quantitativeproteomeanalysisofhumanplasmafollowinginvivolipopolysaccharideadministrationusing16o18olabelingandtheaccuratemassandtimetagapproach‏ ‎‡A Quantitative proteome analysis of human plasma following in vivo lipopolysaccharide administration using 16O/18O labeling and the accurate mass and time tag approach.‏ ‎‡9 1‏
919 ‎‡a quantitativeproteomicsanalysisofadsorbedplasmaproteinsclassifiesnanoparticleswithdifferentsurfacepropertiesandsize‏ ‎‡A Quantitative proteomics analysis of adsorbed plasma proteins classifies nanoparticles with different surface properties and size‏ ‎‡9 1‏
919 ‎‡a quantitativeproteomicsidentifiesalteredoglcnacylationofstructuralsynapticandmemoryassociatedproteinsinalzheimersdisease‏ ‎‡A Quantitative proteomics identifies altered O-GlcNAcylation of structural, synaptic and memory-associated proteins in Alzheimer's disease‏ ‎‡9 1‏
919 ‎‡a rapidlyassessingthequalityoftargetedproteomicsexperimentsthroughmonitoringstableisotopelabeledstandards‏ ‎‡A Rapidly Assessing the Quality of Targeted Proteomics Experiments through Monitoring Stable-Isotope Labeled Standards.‏ ‎‡9 1‏
919 ‎‡a regulatedphosphosignalingassociatedwithbreastcancersubtypesanddruggability‏ ‎‡A Regulated Phosphosignaling Associated with Breast Cancer Subtypes and Druggability‏ ‎‡9 1‏
919 ‎‡a reproducibleworkflowformultiplexeddeepscaleproteomeandphosphoproteomeanalysisoftumortissuesbyliquidchromatographymassspectrometry‏ ‎‡A Reproducible workflow for multiplexed deep-scale proteome and phosphoproteome analysis of tumor tissues by liquid chromatography-mass spectrometry‏ ‎‡9 1‏
919 ‎‡a reversedphasechromatographywithmultiplefractionconcatenationstrategyforproteomeprofilingofhumanmcf10acells‏ ‎‡A Reversed-phase chromatography with multiple fraction concatenation strategy for proteome profiling of human MCF10A cells‏ ‎‡9 1‏
919 ‎‡a simplesodiumdodecylsulfateassistedsamplepreparationmethodforlcmsbasedproteomicsapplications‏ ‎‡A Simple sodium dodecyl sulfate-assisted sample preparation method for LC-MS-based proteomics applications‏ ‎‡9 1‏
919 ‎‡a spatialmappingoftheneuriteandsomaproteomesrevealsafunctionalcdc42racregulatorynetwork‏ ‎‡A Spatial mapping of the neurite and soma proteomes reveals a functional Cdc42/Rac regulatory network‏ ‎‡9 1‏
919 ‎‡a strategyfordegradomicpeptidomicanalysisofhumanbloodplasma‏ ‎‡A Strategy for degradomic-peptidomic analysis of human blood plasma‏ ‎‡9 1‏
919 ‎‡a surfactantassisted1potsamplepreparationforlabelfreesinglecellproteomics‏ ‎‡A Surfactant-assisted one-pot sample preparation for label-free single-cell proteomics‏ ‎‡9 1‏
919 ‎‡a tandemmasstaglabelingfacilitatesreversedphaseliquidchromatographymassspectrometryanalysisofhydrophilicphosphopeptides‏ ‎‡A Tandem Mass Tag Labeling Facilitates Reversed-Phase Liquid Chromatography-Mass Spectrometry Analysis of Hydrophilic Phosphopeptides‏ ‎‡9 1‏
919 ‎‡a targetedquantificationofphosphorylationdynamicsinthecontextofegfrmapkpathway‏ ‎‡A Targeted Quantification of Phosphorylation Dynamics in the Context of EGFR-MAPK Pathway.‏ ‎‡9 1‏
919 ‎‡a useofaquantitativecysteinylpeptideenrichmenttechnologyforhighthroughputquantitativeproteomics‏ ‎‡A The use of a quantitative cysteinyl-peptide enrichment technology for high-throughput quantitative proteomics.‏ ‎‡9 1‏
919 ‎‡a systematicanalysisofadeepmouseepididymalspermproteome‏ ‎‡A A systematic analysis of a deep mouse epididymal sperm proteome‏ ‎‡9 1‏
919 ‎‡a accuratemassmeasurementsinproteomics‏ ‎‡A Accurate mass measurements in proteomics.‏ ‎‡9 1‏
919 ‎‡a advancesandchallengesinliquidchromatographymassspectrometrybasedproteomicsprofilingforclinicalapplications‏ ‎‡A Advances and challenges in liquid chromatography-mass spectrometry-based proteomics profiling for clinical applications‏ ‎‡9 1‏
919 ‎‡a advancingthesensitivityofselectedreactionmonitoringbasedtargetedquantitativeproteomics‏ ‎‡A Advancing the sensitivity of selected reaction monitoring-based targeted quantitative proteomics‏ ‎‡9 1‏
919 ‎‡a improvedboostingtoamplifysignalwithisobariclabelingibasilstrategyforprecisequantitativesinglecellproteomics‏ ‎‡A An improved Boosting to Amplify Signal with Isobaric Labeling (iBASIL) strategy for precise quantitative single-cell proteomics‏ ‎‡9 1‏
919 ‎‡a integrativeanalysisoftumorproteomicandphosphoproteomicprofilestoexaminetherelationshipsbetweenkinaseactivityandphosphorylation‏ ‎‡A An Integrative Analysis of Tumor Proteomic and Phosphoproteomic Profiles to Examine the Relationships Between Kinase Activity and Phosphorylation‏ ‎‡9 1‏
919 ‎‡a analysisofrecombinantandmodifiedproteinsbycapillaryzoneelectrophoresiscoupledwithelectrosprayionizationtandemmassspectrometry‏ ‎‡A Analysis of recombinant and modified proteins by capillary zone electrophoresis coupled with electrospray ionization tandem mass spectrometry‏ ‎‡9 1‏
919 ‎‡a analysisofserumtotalandfreepsausingimmunoaffinitydepletioncoupledtosrmcorrelationwithclinicalimmunoassaytests‏ ‎‡A Analysis of serum total and free PSA using immunoaffinity depletion coupled to SRM: correlation with clinical immunoassay tests‏ ‎‡9 1‏
919 ‎‡a antibodyfreetargetedmassspectrometricapproachforquantificationofproteinsatlowpicogrampermilliliterlevelsinhumanplasmaserum‏ ‎‡A Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum‏ ‎‡9 1‏
919 ‎‡a utilizinghumanbloodplasmaforproteomicbiomarkerdiscovery‏ ‎‡A Utilizing human blood plasma for proteomic biomarker discovery‏ ‎‡9 1‏
919 ‎‡a applicationoffreeflowelectrophoresistothepurificationoftrichosanthinfromacrudeproductofacetonefractionalprecipitation‏ ‎‡A Application of free-flow electrophoresis to the purification of trichosanthin from a crude product of acetone fractional precipitation.‏ ‎‡9 1‏
919 ‎‡a automatednanoflow2dimensionalreversedphaseliquidchromatographysystemenablesindepthproteomeandphosphoproteomeprofilingofnanoscalesamples‏ ‎‡A Automated Nanoflow Two-Dimensional Reversed-Phase Liquid Chromatography System Enables In-Depth Proteome and Phosphoproteome Profiling of Nanoscale Samples‏ ‎‡9 1‏
919 ‎‡a bloodpeptidomedegradomeprofileofbreastcancer‏ ‎‡A Blood peptidome-degradome profile of breast cancer‏ ‎‡9 1‏
919 ‎‡a boostingtoamplifysignalwithisobariclabeling‏ ‎‡A Boosting to Amplify Signal with Isobaric Labeling‏ ‎‡9 1‏
919 ‎‡a boostingtoamplifysignalwithisobariclabelingbasilstrategyforcomprehensivequantitativephosphoproteomiccharacterizationofsmallpopulationsofcells‏ ‎‡A Boosting to Amplify Signal with Isobaric Labeling (BASIL) Strategy for Comprehensive Quantitative Phosphoproteomic Characterization of Small Populations of Cells.‏ ‎‡9 1‏
919 ‎‡a carrierassistedsingletubeprocessingapproachfortargetedproteomicsanalysisoflownumbersofmammaliancells‏ ‎‡A Carrier-Assisted Single-Tube Processing Approach for Targeted Proteomics Analysis of Low Numbers of Mammalian Cells‏ ‎‡9 1‏
919 ‎‡a characterizationofthemousebrainproteomeusingglobalproteomicanalysiscomplementedwithcysteinylpeptideenrichment‏ ‎‡A Characterization of the mouse brain proteome using global proteomic analysis complemented with cysteinyl-peptide enrichment‏ ‎‡9 1‏
919 ‎‡a deepdivetargetedquantificationforultrasensitiveanalysisofproteinsinnondepletedhumanbloodplasmaserumandtissues‏ ‎‡A Deep-Dive Targeted Quantification for Ultrasensitive Analysis of Proteins in Nondepleted Human Blood Plasma/Serum and Tissues.‏ ‎‡9 1‏
919 ‎‡a detectionofheadandneckcancerbasedonlongitudinalchangesinserumproteinabundance‏ ‎‡A Detection of head and neck cancer based on longitudinal changes in serum protein abundance‏ ‎‡9 1‏
919 ‎‡a distinctcerebrospinalfluidproteomesdifferentiateposttreatmentlymediseasefromchronicfatiguesyndrome‏ ‎‡A Distinct cerebrospinal fluid proteomes differentiate post-treatment lyme disease from chronic fatigue syndrome‏ ‎‡9 1‏
919 ‎‡a enhanceddetectionoflowabundancehumanplasmaproteinsusingatandemigy12supermiximmunoaffinityseparationstrategy‏ ‎‡A Enhanced detection of low abundance human plasma proteins using a tandem IgY12-SuperMix immunoaffinity separation strategy.‏ ‎‡9 1‏
919 ‎‡a enhancedsensitivityforselectedreactionmonitoringmassspectrometrybasedtargetedproteomicsusingadualstageelectrodynamicionfunnelinterface‏ ‎‡A Enhanced sensitivity for selected reaction monitoring mass spectrometry-based targeted proteomics using a dual stage electrodynamic ion funnel interface.‏ ‎‡9 1‏
919 ‎‡a establishingtheproteomeofnormalhumancerebrospinalfluid‏ ‎‡A Establishing the proteome of normal human cerebrospinal fluid‏ ‎‡9 1‏
919 ‎‡a evaluationofdifferentialpeptideloadingontandemmasstagbasedproteomicandphosphoproteomicdataquality‏ ‎‡A Evaluation of Differential Peptide Loading on Tandem Mass Tag-Based Proteomic and Phosphoproteomic Data Quality‏ ‎‡9 1‏
919 ‎‡a evaluationofmultiproteinimmunoaffinitysubtractionforplasmaproteomicsandcandidatebiomarkerdiscoveryusingmassspectrometry‏ ‎‡A Evaluation of multiprotein immunoaffinity subtraction for plasma proteomics and candidate biomarker discovery using mass spectrometry.‏ ‎‡9 1‏
919 ‎‡a facilecarrierassistedtargetedmassspectrometricapproachforproteomicanalysisoflownumbersofmammaliancells‏ ‎‡A Facile carrier-assisted targeted mass spectrometric approach for proteomic analysis of low numbers of mammalian cells‏ ‎‡9 1‏
919 ‎‡a facile1potnanoproteomicsforlabelfreeproteomeprofilingof501000mammaliancells‏ ‎‡A Facile One-Pot Nanoproteomics for Label-Free Proteome Profiling of 50-1000 Mammalian Cells‏ ‎‡9 1‏
919 ‎‡a headtoheadcomparisonofserumfractionationtechniques‏ ‎‡A Head-to-Head Comparison of Serum Fractionation Techniques‏ ‎‡9 1‏
919 ‎‡a highdynamicrangecharacterizationofthetraumapatientplasmaproteome‏ ‎‡A High dynamic range characterization of the trauma patient plasma proteome‏ ‎‡9 1‏
919 ‎‡a highthroughputandhighefficiencysamplepreparationforsinglecellproteomicsusinganestednanowellchip‏ ‎‡A High-throughput and high-efficiency sample preparation for single-cell proteomics using a nested nanowell chip‏ ‎‡9 1‏
919 ‎‡a highthroughputcomparativeproteomeanalysisusingaquantitativecysteinylpeptideenrichmenttechnology‏ ‎‡A High-throughput comparative proteome analysis using a quantitative cysteinyl-peptide enrichment technology.‏ ‎‡9 1‏
996 ‎‡2 LC|nr 96029124‏
996 ‎‡2 ISNI|0000000084217063‏
996 ‎‡2 CYT|AC000639875‏
996 ‎‡2 LC|n 91062718‏
996 ‎‡2 ISNI|0000000063444013‏
996 ‎‡2 DNB|1277279640‏
996 ‎‡2 CYT|AC000006646‏
996 ‎‡2 DNB|1135684421‏
996 ‎‡2 DNB|1191518906‏
996 ‎‡2 DNB|1181999340‏
996 ‎‡2 DNB|1262931959‏
996 ‎‡2 LC|no2024054561‏
996 ‎‡2 DNB|1271261413‏
996 ‎‡2 LC|ns2012001739‏
996 ‎‡2 ISNI|0000000048505500‏
996 ‎‡2 LC|nr 00010720‏
996 ‎‡2 CYT|AC000578118‏
996 ‎‡2 ISNI|0000000064372103‏
996 ‎‡2 ISNI|0000000064145293‏
996 ‎‡2 ISNI|0000000032986792‏
996 ‎‡2 DNB|1138374083‏
996 ‎‡2 NSK|000274439‏
996 ‎‡2 NII|DA03018829‏
996 ‎‡2 ISNI|0000000064039335‏
996 ‎‡2 ISNI|0000000072785039‏
996 ‎‡2 LC|n 2018018670‏
996 ‎‡2 ISNI|0000000047641682‏
996 ‎‡2 LC|no2018101730‏
996 ‎‡2 DNB|130065404X‏
996 ‎‡2 DNB|1179128192‏
996 ‎‡2 SUDOC|166236675‏
996 ‎‡2 J9U|987007300362705171‏
996 ‎‡2 LC|no2006060170‏
996 ‎‡2 LC|nb2015008241‏
996 ‎‡2 CYT|AC000647628‏
996 ‎‡2 DNB|1277307547‏
996 ‎‡2 ISNI|0000000447425882‏
996 ‎‡2 BIBSYS|98074015‏
996 ‎‡2 DNB|1259473856‏
996 ‎‡2 LC|no2019180055‏
996 ‎‡2 LC|n 2016063348‏
996 ‎‡2 BIBSYS|4052697‏
996 ‎‡2 LC|nb2016009086‏
996 ‎‡2 DNB|1027700373‏
996 ‎‡2 DNB|1185447466‏
996 ‎‡2 SUDOC|081201192‏
996 ‎‡2 ISNI|0000000040350495‏
996 ‎‡2 NSK|000704376‏
996 ‎‡2 LC|n 80161896‏
996 ‎‡2 ISNI|0000000064201419‏
996 ‎‡2 LC|nr 90024174‏
996 ‎‡2 J9U|987007443823105171‏
996 ‎‡2 ISNI|0000000107374572‏
996 ‎‡2 DNB|1053946511‏
996 ‎‡2 NII|DA08112711‏
996 ‎‡2 LC|no2015023025‏
996 ‎‡2 DNB|1238641245‏
996 ‎‡2 LC|n 85360102‏
996 ‎‡2 SUDOC|272582492‏
996 ‎‡2 SUDOC|28082162X‏
996 ‎‡2 CYT|AC000655459‏
996 ‎‡2 CYT|AC000656529‏
996 ‎‡2 ISNI|0000000063435475‏
996 ‎‡2 ISNI|0000000064254537‏
996 ‎‡2 ISNI|0000000435655015‏
996 ‎‡2 LC|n 2007038778‏
996 ‎‡2 LC|n 2004059283‏
996 ‎‡2 LC|nr 96009078‏
996 ‎‡2 J9U|987007441416805171‏
996 ‎‡2 SUDOC|086757075‏
996 ‎‡2 LC|nr 96039854‏
996 ‎‡2 DNB|138006342‏
996 ‎‡2 ISNI|0000000064146229‏
996 ‎‡2 DNB|1218790083‏
996 ‎‡2 DNB|1207932302‏
996 ‎‡2 BNC|981061178876506706‏
996 ‎‡2 RERO|A011583485‏
996 ‎‡2 LC|no2011090584‏
996 ‎‡2 BIBSYS|90146861‏
996 ‎‡2 ISNI|0000000382266154‏
996 ‎‡2 DNB|1237294711‏
996 ‎‡2 ISNI|0000000064028628‏
996 ‎‡2 SUDOC|190834099‏
996 ‎‡2 CAOONL|ncf10161193‏
996 ‎‡2 LC|n 2024041149‏
996 ‎‡2 ISNI|0000000063511992‏
996 ‎‡2 J9U|987007343556805171‏
996 ‎‡2 SUDOC|192912577‏
996 ‎‡2 ISNI|0000000063877855‏
996 ‎‡2 NTA|142899526‏
996 ‎‡2 LC|no2006110059‏
996 ‎‡2 LC|no2018118318‏
996 ‎‡2 CYT|AC000243188‏
996 ‎‡2 LC|no2015041365‏
996 ‎‡2 ISNI|0000000371439646‏
996 ‎‡2 ISNI|0000000064149489‏
996 ‎‡2 LC|n 88063797‏
996 ‎‡2 ISNI|0000000357579175‏
996 ‎‡2 ISNI|0000000120509662‏
996 ‎‡2 NLA|000035402094‏
996 ‎‡2 ISNI|0000000063915815‏
996 ‎‡2 LC|n 2023041978‏
996 ‎‡2 CYT|AC000223018‏
996 ‎‡2 DNB|143852736‏
996 ‎‡2 DNB|1161757392‏
996 ‎‡2 NSK|000340627‏
996 ‎‡2 LC|no2008028072‏
996 ‎‡2 ISNI|0000000063336725‏
996 ‎‡2 DNB|1015094236‏
996 ‎‡2 PLWABN|9810535420705606‏
996 ‎‡2 LC|n 82057432‏
996 ‎‡2 DNB|1100736271‏
996 ‎‡2 DNB|1337389064‏
996 ‎‡2 ISNI|0000000382846968‏
996 ‎‡2 SZ|1137270233‏
996 ‎‡2 LC|nr 93034286‏
996 ‎‡2 LNB|LNC10-000344376‏
996 ‎‡2 DNB|1331219477‏
996 ‎‡2 SUDOC|073716332‏
996 ‎‡2 DNB|1175143197‏
996 ‎‡2 PLWABN|9810686205305606‏
996 ‎‡2 LC|n 84021298‏
996 ‎‡2 ISNI|0000000063726862‏
996 ‎‡2 LC|n 2017009842‏
996 ‎‡2 DNB|1232334243‏
996 ‎‡2 PLWABN|9813165016405606‏
996 ‎‡2 NDL|031627099‏
996 ‎‡2 BIBSYS|3083396‏
996 ‎‡2 DNB|1194583172‏
996 ‎‡2 DNB|1158082592‏
996 ‎‡2 LC|n 82039451‏
996 ‎‡2 ISNI|0000000064186810‏
996 ‎‡2 DNB|1144977096‏
996 ‎‡2 LC|no2011146069‏
996 ‎‡2 ISNI|000000006334643X‏
996 ‎‡2 BNF|15794992‏
996 ‎‡2 NTA|364154845‏
996 ‎‡2 ISNI|0000000064169308‏
996 ‎‡2 BNF|15535733‏
996 ‎‡2 ISNI|0000000401986246‏
996 ‎‡2 PLWABN|9810575968805606‏
996 ‎‡2 LNB|LNC10-000180701‏
996 ‎‡2 LC|nb2016011493‏
996 ‎‡2 DNB|1054737223‏
996 ‎‡2 LC|nr 91018939‏
996 ‎‡2 LC|no2008185515‏
996 ‎‡2 ISNI|0000000064083432‏
996 ‎‡2 BIBSYS|7077646‏
996 ‎‡2 ISNI|0000000382449970‏
996 ‎‡2 PLWABN|9810554449405606‏
996 ‎‡2 ISNI|0000000064274466‏
996 ‎‡2 LC|n 88027024‏
996 ‎‡2 DNB|1299321798‏
996 ‎‡2 LC|n 90669005‏
996 ‎‡2 LC|nr 93021714‏
996 ‎‡2 ISNI|0000000381726518‏
996 ‎‡2 ISNI|0000000079693866‏
996 ‎‡2 DNB|1047134764‏
996 ‎‡2 ISNI|0000000072938373‏
996 ‎‡2 ISNI|0000000080010751‏
996 ‎‡2 LC|no2013016296‏
996 ‎‡2 LC|nr 93051497‏
996 ‎‡2 KRNLK|KAC200109063‏
996 ‎‡2 PLWABN|9813318739105606‏
996 ‎‡2 ISNI|0000000064134471‏
996 ‎‡2 RERO|A003525901‏
996 ‎‡2 LC|no2020126782‏
996 ‎‡2 ISNI|0000000500991323‏
996 ‎‡2 DNB|1137270233‏
996 ‎‡2 NUKAT|n 2016145493‏
996 ‎‡2 DNB|1312860103‏
996 ‎‡2 DNB|1089148283‏
996 ‎‡2 CYT|AC000244051‏
996 ‎‡2 LC|no2017137648‏
996 ‎‡2 DNB|1067157557‏
996 ‎‡2 ISNI|0000000063997320‏
996 ‎‡2 J9U|987007316240505171‏
996 ‎‡2 SUDOC|229715141‏
996 ‎‡2 ISNI|0000000495511558‏
996 ‎‡2 ISNI|0000000118038486‏
996 ‎‡2 NKC|ntk20211106270‏
996 ‎‡2 ISNI|0000000064100327‏
996 ‎‡2 DNB|1315542374‏
996 ‎‡2 DNB|1062753828‏
996 ‎‡2 ISNI|0000000446230469‏
996 ‎‡2 DNB|1222168804‏
996 ‎‡2 J9U|987007318846205171‏
996 ‎‡2 ISNI|0000000064321189‏
996 ‎‡2 ISNI|0000000073947845‏
996 ‎‡2 ISNI|0000000384862953‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏